Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Prosjektiv Randomisert Evaluering og Behandling av Tidlig Aterosklerose (PRE-EMPT) (PRE-EMPT)

6. november 2026 oppdatert av: Duke University

Prospektiv Randomisert Vurdering og Behandling av Tidlig Aterosklerose

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.

PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:

  1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.

    • Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
    • Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
  2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.

    • Rosuvastatin 20 mg: a cholesterol-lowering medicine
    • Colchicine 0.5 mg: a medication that lowers inflammation

Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.

Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.

Studieoversikt

Detaljert beskrivelse

The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.

Studietype

Intervensjonell

Registrering (Antatt)

1500

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35205
        • Rekruttering
        • University of Alabama at Birmingham
        • Hovedetterforsker:
          • Kevin Riggs, MD
        • Ta kontakt med:
      • Mobile, Alabama, Forente stater, 36608
        • Rekruttering
        • Cardiology Associates
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jason Cole, MD
    • California
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • University of California, Los Angeles
        • Ta kontakt med:
        • Hovedetterforsker:
          • Karol Watson, MD
      • Los Angeles, California, Forente stater, 90502
        • Rekruttering
        • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthew Budoff, MD
    • Georgia
      • Hiram, Georgia, Forente stater, 30141
        • Rekruttering
        • Wellstar Kennestone Hospital
        • Hovedetterforsker:
          • Frank Corrigan, MD
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago
        • Hovedetterforsker:
          • Tamar Polonsky, MD
        • Ta kontakt med:
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Har ikke rekruttert ennå
        • Johns Hopkins University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Blaha, MD
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital Brigham
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Honigberg, MD
    • Minnesota
      • Duluth, Minnesota, Forente stater, 55805
        • Rekruttering
        • Essentia Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Catherine Benzinger, MD
    • New York
      • Mount Kisco, New York, Forente stater, 10549
        • Har ikke rekruttert ennå
        • Northern Westchester Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dina Katz, MD
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Weill Cornell Medicine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sam Kim, MD
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • New York University Langone
        • Hovedetterforsker:
          • Harmony Reynolds, MD
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Hospital
        • Hovedetterforsker:
          • Nishant Shah, MD
        • Ta kontakt med:
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Rekruttering
        • Wake Forest University, Advocate Health
        • Hovedetterforsker:
          • Michael Shapiro, MD
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Har ikke rekruttert ennå
        • Oregon Health and Sciences University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maros Ferencik, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Har ikke rekruttert ennå
        • Thomas Jefferson University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chris Chambers, MD
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Hovedetterforsker:
          • Anum Saeed, MD
        • Ta kontakt med:
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Rekruttering
        • Medical University of South Carolina (MUSC)
        • Hovedetterforsker:
          • Sheldon Litwin, MD
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Har ikke rekruttert ennå
        • Vanderbilt University
        • Hovedetterforsker:
          • Deepak Gupta, MD
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Houston Methodist Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Khurrrram Nasir, MD
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • University of Virginia (UVA)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Todd Villines, MD
      • Fairfax, Virginia, Forente stater, 22031
        • Har ikke rekruttert ennå
        • Inova Health System
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jared Spitz, MD
    • Wisconsin
      • Marshfield, Wisconsin, Forente stater, 54449
        • Rekruttering
        • Marshfield Clinical Research Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jeff VanWormer

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 60 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Women aged 40-60 years; Men aged 30-50 years
  2. Willing and able to provide informed consent and comply with study procedures
  3. Smart phone user
  4. Use of highly effective contraception by females with reproductive potential.
  5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
  6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab

Exclusion Criteria:

  1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
  2. Current symptoms thought to be from CAD
  3. PREVENT ASCVD 10-year risk ≥5% (if known)
  4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
  5. LDL-C ≥190mg/dL (most recent, if known)
  6. HIV (if known)
  7. Severe liver disease or untreated Hepatitis C infection (if known)
  8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years
  9. eGFR <45mL/min/1.73m2 (if known)
  10. AST or ALT >1.5x the upper limit of normal (if known)
  11. BMI>40kg/m2 or unable to have a CCTA scan for any reason
  12. Allergy to iodinated intravenous contrast or other contraindication to CCTA
  13. Current or previous use of lipid lowering therapy or colchicine
  14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
  15. Systemic cancer undergoing active treatment
  16. PREVENT ASCVD 10-year risk ≥5%
  17. eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
  18. Hemoglobin A1c ≥6.5% per baseline labs
  19. LDL-C ≥190mg/dL per baseline labs
  20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
  21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
  22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: rosuvastatin 20mg plus colchicine-matched placebo

statin plus placebo (two pills once daily)

Statin

Andre navn:
  • Crestor

Placebo, non-active, drug-matched

Eksperimentell: colchicine 0.5mg plus rosuvastatin-matched placebo

anti-inflammatory plus placebo (two pills once daily)

Placebo, non-active, drug-matched

Anti-inflammatory

Andre navn:
  • Lodoco
Eksperimentell: rosuvastatin 20mg plus colchicine 0.5mg

statin plus anti-inflammatory (two pills once daily)

Statin

Andre navn:
  • Crestor

Anti-inflammatory

Andre navn:
  • Lodoco
Placebo komparator: placebo plus placebo

Placebo and placebo (two pills once daily)

Placebo, non-active, drug-matched

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tidsramme: 2 years

Plaque volume in mm3 in each group

2 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Endring i LDL-kolesterol (low-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
Baseline til 2 år
Endring i ikke-HDL-kolesterol (high-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
Baseline til 2 år
Number of participants with Drug Discontinuation
Tidsramme: Up to 2 years

Drug Tolerability outcome

Up to 2 years
Overall drug treatment adherence
Tidsramme: Up to 2 years

Number of days on study drugs

Up to 2 years
Safety events of special interest
Tidsramme: Up to 2 years

Number of safety events of special interest per group

Up to 2 years
Total plaque volume
Tidsramme: Up to 2 years

Plaque volume in mm3 per group

Up to 2 years
Low-attenuation plaque volume
Tidsramme: Up to 2 years

Low attenuated plaque volume in mm3 per group

Up to 2 years
Calcified plaque volume
Tidsramme: Up to 2 years

Calcified plaque volume in mm3 per group

Up to 2 years
Number of participants with stenosis
Tidsramme: Up to 2 years

Number of participants with stenosis per group

Up to 2 years
Segment involvement score
Tidsramme: Up to 2 years

Average score per group

Up to 2 years
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tidsramme: Up to 2 years

Number of participants with each plaque composition description per group

Up to 2 years
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tidsramme: Up to 2 years

Number of participants with each plaque feature (high-risk) per group

Up to 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. juli 2026

Primær fullføring (Antatt)

1. juli 2031

Studiet fullført (Antatt)

1. juli 2031

Datoer for studieregistrering

Først innsendt

14. november 2025

Først innsendt som oppfylte QC-kriteriene

14. november 2025

Først lagt ut (Faktiske)

18. november 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere